Literature DB >> 1335044

Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.

D S Fulton1, R C Urtasun, I Scott-Brown, E S Johnson, B Mielke, B Curry, D Huyser-Wierenga, J Hanson, M Feldstein.   

Abstract

We attempted to show a dose effect relationship for radiation therapy by treating patients harbouring malignant glioma with increasing doses of radiation in a step-wise fashion. We postulated that no increase in delayed toxicity would be seen because we used hyperfractionation technique. Between January 1981 and December 1988 we treated 280 patients three times daily at 4 hour intervals. 100 patients received a total dose of 6141 cGy, 73 patients received 7120 cGy, and 107 patients received 8000 cGy. CCNU was given at the time of tumor progression following radiotherapy. Median time to tumor progression was 28 weeks for patients who received 6141 cGy, 27 weeks for patients who received 7120 cGy and 36 weeks for patients who received 8000 cGy. Median survival was 46 weeks for patients who received 6141 cGy, 38 weeks for patients who received 7120 cGy and 45 weeks for patients who received 8000 cGy. There was no statistically significant difference in either time to tumor progression or survival among the three treatment arms and no dose response effect was seen. There was no increase in delayed radiation toxicity when the total radiation dose was increased up to 8000 cGy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335044     DOI: 10.1007/bf00170946

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  Cell cycle redistribution as a factor in multifraction irradiation.

Authors:  H R Withers
Journal:  Radiology       Date:  1975-01       Impact factor: 11.105

2.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

3.  High dose radiation therapy in the treatment of malignant gliomas: final report.

Authors:  O M Salazar; P Rubin; M L Feldstein; R Pizzutiello
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-10       Impact factor: 7.038

4.  Accelerated fractionation vs hyperfractionation: rationales for several treatments per day.

Authors:  H D Thames; L J Peters; H R Withers; G H Fletcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-02       Impact factor: 7.038

5.  Superfractionation: its rationale and anticipated benefits.

Authors:  B G Douglas
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-07       Impact factor: 7.038

6.  Hyperfractionation.

Authors:  H R Withers; L J Peters; H D Thames; G H Fletcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-10       Impact factor: 7.038

7.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.

Authors:  D F Nelson; M Diener-West; A S Weinstein; D Schoenfeld; J S Nelson; W T Sause; C H Chang; R Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-10       Impact factor: 7.038

8.  Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial.

Authors:  D G Payne; W J Simpson; C Keen; M E Platts
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

9.  Misonidazole combined with hyperfractionation in the management of malignant glioma.

Authors:  D S Fulton; R C Urtasun; K H Shin; P H Geggie; H Thomas; P J Muller; J Moody; H Tanasichuk; B Mielke; E Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

10.  Selection bias in clinical trials of anaplastic glioma.

Authors:  M J Winger; D R Macdonald; S C Schold; J G Cairncross
Journal:  Ann Neurol       Date:  1989-10       Impact factor: 10.422

View more
  11 in total

Review 1.  Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Authors:  Sabine Mueller; Susan Chang
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  The rationale and requirements for the development of boron neutron capture therapy of brain tumors.

Authors:  A H Soloway; R F Barth; R A Gahbauer; T E Blue; J H Goodman
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

3.  Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy.

Authors:  Jacob Y Shin; Aidnag Z Diaz
Journal:  J Neurooncol       Date:  2016-07-11       Impact factor: 4.130

Review 4.  Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.

Authors:  Steve Braunstein; David Raleigh; Ranjit Bindra; Sabine Mueller; Daphne Haas-Kogan
Journal:  J Neurooncol       Date:  2017-03-29       Impact factor: 4.130

5.  Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.

Authors:  J Dawn Waters; Brent Rose; David D Gonda; Daniel J Scanderbeg; Michelle Russell; John F Alksne; Kevin Murphy; Bob S Carter; Joshua Lawson; Clark C Chen
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

Review 6.  Recent trends in the radiotherapy of pediatric gliomas.

Authors:  N J Tarbell; J S Loeffler
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

7.  Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams.

Authors:  Yoshinobu Nakagawa; Kyonghon Pooh; Toru Kobayashi; Teruyoshi Kageji; Shinichi Uyama; Akira Matsumura; Hiroaki Kumada
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

Review 8.  Current perspectives in gliomas.

Authors:  C S Brock; M Bower
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.738

9.  Bionanotechnology and the future of glioma.

Authors:  Peter A Chiarelli; Forrest M Kievit; Miqin Zhang; Richard G Ellenbogen
Journal:  Surg Neurol Int       Date:  2015-02-13

10.  Canadian recommendations for the treatment of glioblastoma multiforme.

Authors:  W P Mason; R Del Maestro; D Eisenstat; P Forsyth; D Fulton; N Laperrière; D Macdonald; J Perry; B Thiessen
Journal:  Curr Oncol       Date:  2007-06       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.